Imugene and JW Therapeutics Partner to Advance CAR-T and Oncolytic Virus Therapy for Solid Tumors

Reuters

Nov 28

Imugene and JW <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Partner to Advance CAR-T and Oncolytic Virus Therapy for Solid Tumors

Imugene Limited has announced a strategic collaboration with JW Therapeutics to advance a novel combination therapy for refractory solid tumors. The partnership will evaluate Imugene's onCARlytics (CF33-CD19) oncolytic virus in combination with JW Therapeutics' Carteyva®, an approved CD19-directed autologous CAR-T cell therapy. The initiative includes preclinical studies and a Phase 1 investigator-initiated trial in China, employing a "mark and kill" strategy where the oncolytic virus induces CD19 expression on tumor cells, making them targetable by CAR-T cells. The collaboration aims to generate impactful preclinical and clinical data to explore new treatment paradigms for solid tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imugene Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN34930) on November 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2586208061"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2586208061\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2586208061?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-28 13:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586208061","market":"us","top_or_hot":-1,"title":"Imugene and JW Therapeutics Partner to Advance CAR-T and Oncolytic Virus Therapy for Solid Tumors","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Imugene and JW <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Partner to Advance CAR-T and Oncolytic Virus Therapy for Solid Tumors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IMUOE.AU\">Imugene Limited</a> has announced a strategic collaboration with JW Therapeutics to advance a novel combination therapy for refractory solid tumors. The partnership will evaluate Imugene's onCARlytics (CF33-CD19) oncolytic virus in combination with JW Therapeutics' Carteyva®, an approved CD19-directed autologous CAR-T cell therapy. The initiative includes preclinical studies and a Phase 1 investigator-initiated trial in China, employing a \"mark and kill\" strategy where the oncolytic virus induces CD19 expression on tumor cells, making them targetable by CAR-T cells. The collaboration aims to generate impactful preclinical and clinical data to explore new treatment paradigms for solid tumors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imugene Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN34930) on November 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Imugene and JW Therapeutics Partner to Advance CAR-T and Oncolytic Virus Therapy for Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImugene and JW Therapeutics Partner to Advance CAR-T and Oncolytic Virus Therapy for Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-28 13:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Imugene and JW <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Partner to Advance CAR-T and Oncolytic Virus Therapy for Solid Tumors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IMUOE.AU\">Imugene Limited</a> has announced a strategic collaboration with JW Therapeutics to advance a novel combination therapy for refractory solid tumors. The partnership will evaluate Imugene's onCARlytics (CF33-CD19) oncolytic virus in combination with JW Therapeutics' Carteyva®, an approved CD19-directed autologous CAR-T cell therapy. The initiative includes preclinical studies and a Phase 1 investigator-initiated trial in China, employing a \"mark and kill\" strategy where the oncolytic virus induces CD19 expression on tumor cells, making them targetable by CAR-T cells. The collaboration aims to generate impactful preclinical and clinical data to explore new treatment paradigms for solid tumors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imugene Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN34930) on November 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02126","symbol_name":"药明巨诺-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL6XF6wh:1","article_id":"2586208061","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586208061","pubTimestamp":1764306071,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Imugene Limited has announced a strategic collaboration with JW Therapeutics to advance a novel combination therapy for refractory solid tumors. The partnership will evaluate Imugene's onCARlytics  oncolytic virus in combination with JW Therapeutics' Carteyva, an approved CD19-directed autologous CAR-T cell therapy. The initiative includes preclinical studies and a Phase 1 investigator-initiated trial in China, employing a \"mark and kill\" strategy where the oncolytic virus induces CD19 expression on tumor cells, making them targetable by CAR-T cells. The collaboration aims to generate impactful preclinical and clinical data to explore new treatment paradigms for solid tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imugene Limit","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02126":"药明巨诺-B","BK1161":"生物科技","BK1574":"生物医药B类股","BK7067":"生物科技","IMU.AU":"IMUGENE LTD","BK7508":"医药生物股","BK1583":"高瓴概念"},"translate_title":"Imugene与JW Therapeutics合作推进实体瘤CAR-T和溶瘤病毒疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02126":0.9,"IMU.AU":0.9},"content_text":"Imugene and JW Therapeutics Partner to Advance CAR-T and Oncolytic Virus Therapy for Solid Tumors\n    \n\nImugene Limited has announced a strategic collaboration with JW Therapeutics to advance a novel combination therapy for refractory solid tumors. The partnership will evaluate Imugene's onCARlytics (CF33-CD19) oncolytic virus in combination with JW Therapeutics' Carteyva®, an approved CD19-directed autologous CAR-T cell therapy. The initiative includes preclinical studies and a Phase 1 investigator-initiated trial in China, employing a \"mark and kill\" strategy where the oncolytic virus induces CD19 expression on tumor cells, making them targetable by CAR-T cells. The collaboration aims to generate impactful preclinical and clinical data to explore new treatment paradigms for solid tumors.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imugene Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN34930) on November 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}